KBD4466
KBD4466 is an orally active potent TLR7 and TLR8 inhibitor with IC50s of 0.9 nM and 2.8 nM, respectively. KBD4466 inhibits the expression of inflammatory cytokines IL-6 and IFN-α. KBD4466 improves disease progression and survival in the BXSB/MpJ mouse model of Systemic Lupus Erythematosus (SLE) . KBD4466 can be used in the study of autoimmune diseases[1].
Product Specifications
CAS Number
3023713-87-0
UNSPSC
12352005
Target
IFNAR; Interleukin Related; Toll-like Receptor (TLR)
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
CN1CCC(C2=NN=C([C@]34CN(C[C@]3(C4)C(F)(F)F)C5=C6C=CC=NC6=C(C=C5)C#N)O2)CC1
Molecular Formula
C24H23F3N6O
Molecular Weight
468.47
References & Citations
[1]Yuan Y, et al. Discovery of KBD4466, a Selective TLR 7/8 Inhibitor, for the Treatment of Autoimmune Diseases. J Med Chem. 2025 Jul 1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-6; TLR7; TLR8
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
SREBP1, Control Peptide (Sterol Regulatory Element-binding Protein 1, Sterol Regulatory Element-binding Transcription Factor 1, SREBP-1, SREBF1) discontinued
L-α-Phosphatidylcholine β- (pyren-1-yl) hexanoyl-γ-palmitoyl
L-α-Phosphatidylcholine β- (pyren-1-yl) hexanoyl-γ-palmitoyl